Fennec Pharmaceuticals Reports Surge in Q1 2026 Revenue Amid Expanding PEDMARK® Clinical Footprint
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) has announced a significant financial milestone, reporting a robust start to the fiscal year. On May 14, 2026, the specialty pharmaceutical company disclosed its first-quarter financial results for the period ended March 31, 2026, characterized by substantial revenue growth and expanding clinical interest in its core therapeutic offerings.
The company achieved total net revenues of $15.1 million for the first quarter, representing a 73% increase compared to the same period in the previous year. This growth is bolstered by strategic field sales expansions and rising demand for its primary product, PEDMARK®.
Record Demand and Strategic Sales Expansion
A primary driver of Fennec’s recent performance is the increasing market traction of PEDMARK® (sodium thiosulfate injection). The company noted that strategic enhancements to its field force are already yielding tangible results, with record demand for PEDMARK® reported in April 2026.
Management attributed these successes to improved execution and expanded reach. The company’s Fennec HEARS® program is contributing to improved patient access and strong conversion rates, which has directly impacted the number of patients receiving treatment.
Clinical Momentum and ASCO 2026 Participation
Beyond immediate financial gains, Fennec is aggressively pursuing clinical validation across new patient populations. The company has officially initiated a third institution-led clinical study. This study is designed to evaluate the efficacy of PEDMARK® in both adolescent and young adult (AYA) and adult patients specifically dealing with head and neck and testicular cancers.
The scientific community’s interest in the therapy is expected to remain high throughout the year. Fennec confirmed that four abstracts evaluating PEDMARK® will be included in the program for the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
“2026 is a defining period for Fennec, with growing clinical interest in independently evaluating PEDMARK® (sodium thiosulfate injection) across new patient populations and tumor types that reinforces our confidence in its broader potential,” said Jeff Hackman, Chief Executive Officer of Fennec Pharmaceuticals.
Key Takeaways: Q1 2026 Performance
- Revenue Growth: Total net revenues reached $15.1 million, a 73% year-over-year increase.
- Product Demand: PEDMARK® saw record demand in April 2026 following field sales expansion.
- Clinical Expansion: A new institution-led study is underway for head and neck and testicular cancers in AYA and adult populations.
- Scientific Recognition: Four PEDMARK® abstracts are slated for the 2026 ASCO Annual Meeting.
Frequently Asked Questions
What is PEDMARK®?
PEDMARK® is a sodium thiosulfate injection developed by Fennec Pharmaceuticals for use in various clinical applications, including oncology-related treatments.
How has Fennec Pharmaceuticals’ revenue changed year-over-year?
Fennec Pharmaceuticals reported a 73% increase in total net revenues for Q1 2026 compared to the first quarter of the previous year.
Which medical organizations will feature Fennec’s research in 2026?
The American Society of Clinical Oncology (ASCO) will include four abstracts evaluating PEDMARK® in its 2026 Annual Meeting program.
As Fennec Pharmaceuticals moves through 2026, the company appears focused on a dual-track strategy of commercial scaling via its field force and scientific expansion through rigorous clinical evaluation.